Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen, Inc., announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Genzyme, a Sanofi company, announced today that the Australian Therapeutic Goods Administration has approved Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis for patients with active disease defined by clinical or imaging features to slow the accumulation of physical disability and reduce the frequency of clinical relapses.

19 Dec 2013

Sorrento Therapeutics acquires Concortis Biosystems

Sorrento Therapeutics, Inc. announced today that it has completed its acquisition of Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates with site-specific toxin conjugation and consistent drug-antibody ratios. With the close of the deal, Sorrento has issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Based on the closing share price on December 18, 2013, the transaction is valued at $11.3 million.

19 Dec 2013

Randomized control trials to study clinical effectiveness of high dose flu vaccine in nursing homes

One of the highest risk groups for developing pneumonia or even dying from the flu is the elderly, especially in group settings such as nursing homes.

19 Dec 2013

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Sanofi and Regeneron Pharmaceuticals, Inc. today announced an innovative collaboration with the American College of Cardiology focused on enhancing clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Alirocumab is being co-developed by Sanofi and Regeneron.

19 Dec 2013

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013

Researchers produce first definitive evidence that MERS-CoV infects camels

Scientists from the Netherlands and Qatar have produced the first definitive evidence that Middle East respiratory syndrome coronavirus infects camels. The researchers used gene-sequencing techniques to show that three camels from a site where two humans contracted MERS-CoV were infected with the virus.

18 Dec 2013

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals: all pre-specified biological activity measures (e.g. target engagement, effector functions, immune-modulation) were met.

17 Dec 2013

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Biogen Idec (NASDAQ: BIIB) and Samsung Bioepis today announced that through their joint venture, Biogen Idec has exercised its right to enter into an agreement to commercialize anti-TNF biosimilar product candidates in Europe, including biosimilars for widely used therapies to treat conditions such as rheumatoid arthritis and Crohn's disease.

17 Dec 2013

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Testing the efficacy of vaccines in clinical trials takes years, even decades. Yet challenging infections like HIV, malaria and dengue are striking today. To speed up vaccine testing, scientists at the Emory Vaccine Center have established a goal of creating a "vaccine gene chip."

17 Dec 2013

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

16 Dec 2013

MD Anderson researcher earns Breakthrough Prize in Life Sciences

Basic science research that exposed vital details of cancer's defense against the immune system, revealing an entirely new way to combat these diseases, has earned Jim Allison, Ph.D., a Breakthrough Prize in Life Sciences.

14 Dec 2013

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Genzyme, a Sanofi company, announced today that Health Canada has approved Lemtrada (alemtuzumab) for the management of adult patients with relapsing remitting multiple sclerosis, with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies.

13 Dec 2013

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.

13 Dec 2013

Combination therapy safe and active in follicular lymphoma

One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response.

12 Dec 2013

Researchers discover new therapeutic approach for hemophilia

Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition that affects about 50,000 people in the United States and millions more around the world.

12 Dec 2013

Wolfberries appear to interact with vaccine to offer protection against flu virus in older mice

In a study of older mice, wolfberries appear to interact with the influenza vaccine to offer additional protection against the flu virus. The research, led by scientists at the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HNRCA) at Tufts University, suggests the wolfberry may increase the activity of dendritic cells, which play an important role in the ability of the immune system to defend against viral infections.

12 Dec 2013

Antibody News and Research

Further Reading

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Australian Therapeutic Goods Administration approves Genzyme's Lemtrada for multiple sclerosis

Sorrento Therapeutics acquires Concortis Biosystems

Randomized control trials to study clinical effectiveness of high dose flu vaccine in nursing homes

Sanofi and Regeneron Pharmaceuticals team up with ACC to enhance clinical research with alirocumab

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Researchers produce first definitive evidence that MERS-CoV infects camels

arGEN-X reports that Phase Ib cancer study with ARGX-110 antibody meets translational development goals

Biogen joins with Samsung Bioepis to commercialize anti-TNF biosimilar product candidates in Europe

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Combination of ramucirumab and docetaxel fails to delay advanced breast cancer progression

MD Anderson researcher earns Breakthrough Prize in Life Sciences

Health Canada approves Genzyme's Lemtrada for adults with relapsing remitting multiple sclerosis

Cetuximab fails in second-line combination for recurrent NSCLC

Combination therapy safe and active in follicular lymphoma

Researchers discover new therapeutic approach for hemophilia

Wolfberries appear to interact with vaccine to offer protection against flu virus in older mice

Antibodies eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News